Results 11 to 20 of about 35,534 (303)
Sensitivity to cdk1-inhibition is modulated by p53 status in preclinical models of embryonal tumors [PDF]
Oncotarget, 2015 Dysregulation of the cell cycle and cyclin-dependent kinases (cdks) is a hallmark of cancer cells. Intervention with cdk function is currently evaluated as a therapeutic option in many cancer types including neuroblastoma (NB), a common solid tumor of ...
Eggert, Angelika +8 more
core +16 more sources
MYCN Function in Neuroblastoma Development [PDF]
Frontiers in Oncology, 2021 Dysregulated expression of the transcription factor MYCN is frequently detected in nervous system tumors such as childhood neuroblastoma. Here, gene amplification of MYCN is a single oncogenic driver inducing neoplastic transformation in neural crest ...
Jörg Otte +3 more
semanticscholar +4 more sources
Radiogenomics prediction for MYCN amplification in Neuroblastoma: a hypothesis generating study [PDF]
Pediatric Blood & Cancer, 2021 MYCN amplification represents a powerful prognostic factor in neuroblastoma (NB) and may occasionally account for intratumoral heterogeneity. Radiomics is an emerging field of advanced image analysis that aims to extract a large number of quantitative ...
Angela Di Giannatale +9 more
openalex +2 more sources
MYCN Drives a Tumor Immunosuppressive Environment Which Impacts Survival in Neuroblastoma
Frontiers in Oncology, 2021 A wide range of malignancies presents MYCN amplification (MNA) or dysregulation. MYCN is associated with poor prognosis and its over-expression leads to several dysregulations including metabolic reprogramming, mitochondria alteration, and cancer stem ...
Salvatore Raieli +9 more
doaj +2 more sources
Nature Genetics, 2018 Childhood high-risk neuroblastomas with MYCN gene amplification are difficult to treat effectively1. This has focused attention on tumor-specific gene dependencies that underlie tumorigenesis and thus provide valuable targets for the development of novel
Adam D Durbin +2 more
exaly +2 more sources
MYCN and Metabolic Reprogramming in Neuroblastoma
Cancers, 2022 Simple Summary Metabolic reprogramming has a central role in the initiation and progression of cancer, including high-risk neuroblastoma, a deadly childhood malignant tumor of the sympathetic nervous system. This rewiring of cellular metabolism increases
M. Bansal, Anamika Gupta, H. Ding
semanticscholar +3 more sources
MYCN amplification drives an aggressive form of spinal ependymoma
Acta Neuropathologica, 2019 Spinal ependymal tumors form a histologically and molecularly heterogeneous group of tumors with generally good prognosis. However, their treatment can be challenging if infiltration of the spinal cord or dissemination throughout the central nervous ...
David Reza Norali Ghasemi +2 more
exaly +2 more sources
MYCN amplification and ATRX mutations are incompatible in neuroblastoma [PDF]
Nature Communications, 2020 Xiang Chen, Yiping Fan, Beisi Xu
exaly +2 more sources
Functional Difference of MYC and MYCN in Combined Hepatocellular-Cholangiocarcinoma: Regulation of Differentiation by HNF1B. [PDF]
Cancer SciCombined hepatocellular–cholangiocarcinoma (cHCC‐CCA) is a tumor consisting of a mixture of hepatocellular carcinoma and intrahepatic cholangiocarcinoma (CCA) components, but the mechanisms of development are poorly understood. The activation of Myc may be implicated in the formation of cHCC‐CCA and this work demonstrates for the first time that Myc ...
Goto M +10 more
europepmc +2 more sources